Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07031713

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

Sponsor: CARsgen Therapeutics Co., Ltd.

Conditions Systemic Lupus Erythematosus (SLE)

Interventions CAR-T Therapy

Updated 4 times since 2025 Last updated: Nov 18, 2025 Started: Jul 11, 2025 Primary completion: Dec 31, 2026 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Systemic Lupus Erythematosus (SLE), this trial is actively recruiting participants. The trial is conducted by CARsgen Therapeutics Co., Ltd. and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CARsgen Therapeutics Co., Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Data source: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China